Antipodes Partners LTD Humacyte, Inc. Transaction History
Antipodes Partners LTD
- $3 Billion
- Q2 2025
A detailed history of Antipodes Partners LTD transactions in Humacyte, Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 7,174 shares of HUMA stock, worth $13,487. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,174Holding current value
$13,487% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HUMA
# of Institutions
170Shares Held
54.4MCall Options Held
1.1MPut Options Held
808K-
Black Rock Inc. New York, NY7.14MShares$13.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7MShares$13.2 Million0.0% of portfolio
-
State Street Corp Boston, MA4.39MShares$8.26 Million0.0% of portfolio
-
Center Book Partners LP Greenwich, CT3.43MShares$6.45 Million0.42% of portfolio
-
Geode Capital Management, LLC Boston, MA2.95MShares$5.54 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $194M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...